N-acetylcarnosine: RN given refers to (L)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-acetylcarnosine : A dipeptide that is the N-acetyl derivative of carnosine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9903482 |
| CHEMBL ID | 4303521 |
| CHEBI ID | 67249 |
| SCHEMBL ID | 2513184 |
| MeSH ID | M0104402 |
| Synonym |
|---|
| AC-6754 |
| 56353-15-2 |
| n-acetyl carnosine |
| n-acetylcarnosine |
| A8090 |
| (s)-2-(3-acetamidopropanamido)-3-(1h-imidazol-4-yl)propanoic acid |
| n-acetyl-l-carnosine |
| einecs 260-123-2 |
| can-c |
| 0tpn86oqif , |
| cl 1700 |
| n-(n-acetyl-beta-alanyl)-l-histidine |
| unii-0tpn86oqif |
| AKOS016001331 |
| ace cns |
| acetyl carnosine |
| acetyl carnosine [inci] |
| n-acetylcarnosine [who-dd] |
| histidine, n-(n-acetyl-.beta.-alanyl)-, l- |
| l-histidine, n-(n-acetyl-.beta.-alanyl)- |
| l-histidine, n-acetyl-.beta.-alanyl- |
| n-(n-acetyl-.beta.-alanyl)histidine |
| (2s)-2-{[3-(acetylamino)propanoyl]amino}-3-(1h-imidazol-5-yl)propanoic acid |
| n-acetyl-beta-alanyl-l-histidine |
| CHEBI:67249 |
| A-1080 |
| BKAYIFDRRZZKNF-VIFPVBQESA-N |
| SCHEMBL2513184 |
| W-105525 |
| DTXSID30204897 |
| AKOS025402233 |
| n-a-acetyl-n-b-alanyl-l-histidine |
| (s)-2-(3-acetylamino-propionylamino)-3-(3h-imidazol-4-yl)-propionic acid |
| mfcd04039376 |
| (2s)-2-{[3-(acetylamino)propanoyl]amino}-3-(1h-imidazol-5-yl)propanoic acid, aldrichcpr |
| canc |
| nalpha-(n-acetyl-beta-alanyl)-l-histidine |
| BCP19530 |
| Q4673297 |
| HY-133026 |
| CS-0109492 |
| (s)-2-(3-acetamidopropanamido)-3-(1h-imidazol-4-yl)propanoicacid |
| AS-15852 |
| AMY25381 |
| (3-acetamidopropanoyl)-l-histidine |
| ac-beta-ala-his-oh |
| l-histidine, n-acetyl-b-alanyl- |
| CHEMBL4303521 |
| (2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Patients and the public expect that safe and cost-effective cataract medical care with N-acetylcarnosine therapeutic platform should be commissioned for them." | ( State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatm Babizhayev, MA; Kasus-Jacobi, A, 2009) | 0.82 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The method was applied to determine the pharmacokinetic parameters and the time-course of N-acetylcarnosine and L-carnosine-related product in the eye, following a single dosage of topical ocular administration of peptide." | ( Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention. Babizhayev, MA, 2005) | 0.75 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " (IVP), aim at enhancing the drug bioavailability by ensuring a prolonged retention of the medication in the eye, and/or by facilitating transcorneal penetration." | ( Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Babizhayev, MA, 2008) | 0.59 |
| " Novel approaches to ocular drug delivery increasing intraocular bioavailability of N-acetylcarnosine biologically activated metabolite carnosine become an integral development ensuring prolonged retention of the medication in the mucoadhesive precorneal area and facilitating transcorneal penetration of the natural dipeptide with the corneal promoters." | ( Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform. Babizhayev, MA, 2012) | 0.85 |
| " The purpose of this study was the improvement of the topical bioavailability of the hydrophilic dipeptides L-carnosine and its related compound N-acetyl-L-carnosine." | ( Dermal peptide delivery using enhancer molecules and colloidal carrier systems--part I: carnosine. Goebel, AS; Neubert, RH; Schmaus, G; Wohlrab, J, 2012) | 0.38 |
The research utilizing the N-acetylcarnosine lubricant eye drops powerful therapeutic platform. The findings related to the intraocular uptake exposure sources as well as a timing dosage and duration systemic absorption of said preparation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The method was applied to determine the pharmacokinetic parameters and the time-course of N-acetylcarnosine and L-carnosine-related product in the eye, following a single dosage of topical ocular administration of peptide." | ( Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention. Babizhayev, MA, 2005) | 0.75 |
| "The research utilizing the N-acetylcarnosine lubricant eye drops powerful therapeutic platform provides the findings related to the intraocular uptake exposure sources as well as a timing dosage and duration systemic absorption of said preparation from the conjunctional sac reaching the hypothalamus with activities transfer into the hypothalamic-neuroendocrine pathways affecting across the hypothalamus metabolic pathway the telomere biology and cataract disease occurrence, reversal and prevention and the average expected lifespan of an individual." | ( Telomere Attrition in Human Lens Epithelial Cells Associated with Oxidative Stress Provide a New Therapeutic Target for the Treatment, Dissolving and Prevention of Cataract with N-Acetylcarnosine Lubricant Eye Drops. Kinetic, Pharmacological and Activity- Babizhayev, MA; Yegorov, YE, 2016) | 0.92 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (7.55) | 18.7374 |
| 1990's | 5 (9.43) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 22 (41.51) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (43.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (11.86%) | 5.53% |
| Reviews | 15 (25.42%) | 6.00% |
| Case Studies | 1 (1.69%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 36 (61.02%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||